Protocol development(base) and protocol implementation(options 1-6) relative to protocol 14-0112, a phase II double-blind randomized placebo controlled trial to evaluate the safety, reactogenicity,…
Ended Awarded Last action
- Contract number
- HHSN27200009
- Awardee
-
Childrens Hospital Medical Center UEI JZD1HLM2ZU83
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $709,189
Award facts
- Opportunity
-
- NIAIDDMIDNIHAI2012144 Solicitation number
- Vaccine and treatment evaluation units (vteu) Award Notice · Posted Mar 29, 2012
- Contract value 40% obligated
-
- $709,189.48 Current, with exercised options
- $1,763,776.48 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 7 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Cincinnati, OH 45229, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$87,550 | |
| Funding Only Action | $195,030 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $512,034 | |
| Original award | $89,675 |
About this award
This federal contract award is for Protocol Development (base) and Protocol Implementation (options 1-6) services related to a Phase II clinical trial (Protocol 14-0112) to evaluate the safety, reactogenicity, and immunogenicity of the M-001 influenza A/H7N9 vaccine in healthy volunteers. The award was made by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, under the Vaccine and Treatment Evaluation Units (VTEU) program. The prime contractor is Childrens Hospital Medical Center, a non-profit pediatric hospital and research center in Cincinnati, Ohio. The contract has a ceiling value of $1,763,776.48 and a period of performance through December 31, 2019. No set-aside designations were used for this award. As a major recipient of federal funding, Childrens Hospital Medical Center has extensive expertise in pediatric medicine, clinical trials, and vaccine research, and frequently collaborates with government and academic partners on critical public health initiatives.
Description
Protocol development(base) and protocol implementation(options 1-6) relative to protocol 14-0112, a phase II double-blind randomized placebo controlled trial to evaluate the safety, reactogenicity, and immunogenicity of one or two doses of m-001 followed by one or two doses of an influenza a/H7N9 vaccine in healthy volunteers.
Quick answers
Who was awarded contract HHSN27200009?
HHSN27200009 was awarded to Childrens Hospital Medical Center by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on January 13, 2016.
How much is contract HHSN27200009 worth?
The government has obligated $709,189 on HHSN27200009. Its potential value, with all options, is $1,763,776.
Is contract HHSN27200009 an order under another contract?
Yes. HHSN27200009 is a delivery order under HHSN272201300016I, an indefinite delivery contract, on Vaccine and Treatment Evaluation Units (VTEU).
Was contract HHSN27200009 competed?
The extent of competition for HHSN27200009 was full and open competition. The government received 7 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award